Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies

Kaposi Sarcoma Mimicking a Lingual Lesion in an HIV-Negative Patient: A Case Report

“…The viral life cycle of KHSV has two phases: latency and lytic replication. In KS, KSHV exists primarily in a state of latency; for this reason, the disease likely takes a more indolent course as compared to HIV-associated or post-transplant KS, where an immunocompromise occurs [8]. Regarding the prevalence of human herpesviruses (HHV) in tonsils, a study reported KSHV was rarely detected in tonsil brushings collected from non-cancerous immunocompetent individuals, with a prevalence of 0.8% in children and 0.7% in adults, showing HHVs like EBV, HHV6B, and HHV7 are frequent in the tonsils of immunocompetent individuals, in contrast with other herpesviruses, like KSHV, that are rarely detected [9].…”

HSP110 Inhibition in Primary Effusion Lymphoma Cells: One Molecule, Many Pro-Survival Targets

“…Regarding HSP110, whose targeting seems to be particularly efficient at impairing the survival of Burkitt lymphoma [19], there are no commercially available inhibitors either. In this study, we used a silencing approach to investigate the role of HSP110 and showed for the first time that it plays a key role in the survival of PEL cells, an aggressive KSHV-associated lymphoma, characterized by a poor response to conventional chemotherapies [27]. We discovered that, in addition to its already known capacity to reduce c-Myc expression level, HSP110 silencing downregulates key DDR molecules, belonging either to HR and NHEJ, namely BRCA-1 and Ku70.…”